Abiraterone acetate is a targeted endocrine therapy widely used for treating advanced prostate cancer in adult men, especially those with metastatic or high-risk disease that has stopped responding to standard hormone treatments. It works by inhibiting a key enzyme involved in the production of androgens (male hormones), which slows the growth of hormone-driven prostate cancer cells. Abiraterone is typically combined with prednisone or another steroid to further support therapy and is not classified as chemotherapy, but is an essential part of modern prostate cancer management.